• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response by Yang and Gu to Letter Regarding Article, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)".

作者信息

Yang Xueli, Gu Dongfeng

机构信息

From Department of Epidemiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Circulation. 2017 Mar 28;135(13):e822-e823. doi: 10.1161/CIRCULATIONAHA.117.027318.

DOI:10.1161/CIRCULATIONAHA.117.027318
PMID:28348098
Abstract
摘要

相似文献

1
Response by Yang and Gu to Letter Regarding Article, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)".
Circulation. 2017 Mar 28;135(13):e822-e823. doi: 10.1161/CIRCULATIONAHA.117.027318.
2
Letter by Koh Regarding Articles, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)" and "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population".科关于文章《预测中国人群动脉粥样硬化性心血管疾病的10年风险：中国-PAR项目（中国动脉粥样硬化性心血管疾病风险预测）》及《二级预防人群复发性血管事件估计10年风险及残余风险分布》的信函
Circulation. 2017 Mar 28;135(13):e818-e819. doi: 10.1161/CIRCULATIONAHA.116.026360.
3
Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China).预测中国人群动脉粥样硬化性心血管疾病 10 年风险：中国 PAR 项目（中国 ASCVD 风险预测）。
Circulation. 2016 Nov 8;134(19):1430-1440. doi: 10.1161/CIRCULATIONAHA.116.022367. Epub 2016 Sep 28.
4
Prediction of 10-year Atherosclerotic Cardiovascular Disease Risk among Adults Aged 40-79 Years in China: a Nationally Representative Survey.中国40-79岁成年人10年动脉粥样硬化性心血管疾病风险预测：一项全国代表性调查。
Biomed Environ Sci. 2017 Apr;30(4):244-254. doi: 10.3967/bes2017.034.
5
Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study.中国北方农村人群动脉粥样硬化性心血管病风险预测模型的表现：来自房山队列研究的结果。
Am Heart J. 2019 May;211:34-44. doi: 10.1016/j.ahj.2019.01.009. Epub 2019 Feb 5.
6
Risk stratification of atherosclerotic cardiovascular disease in Chinese adults.中国成年人动脉粥样硬化性心血管疾病的风险分层
Chronic Dis Transl Med. 2016 Oct 21;2(2):102-109. doi: 10.1016/j.cdtm.2016.10.001. eCollection 2016 Jun.
7
Predicting lifetime risk for developing atherosclerotic cardiovascular disease in Chinese population: the China-PAR project.预测中国人群发生动脉粥样硬化性心血管疾病的终生风险：中国-PAR项目
Sci Bull (Beijing). 2018 Jun 30;63(12):779-787. doi: 10.1016/j.scib.2018.05.020. Epub 2018 May 25.
8
[Accuracy of the China-PAR and WHO risk models in predicting the ten-year risks of cardiovascular disease in the Chinese population].[中国-PAR和WHO风险模型预测中国人群心血管疾病十年风险的准确性]
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Aug 10;43(8):1275-1281. doi: 10.3760/cma.j.cn112338-20211206-00952.
9
[Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].[中国北方农村人群心血管疾病一级预防中不同筛查策略的有效性]
Beijing Da Xue Xue Bao Yi Xue Ban. 2018 Jun 18;50(3):443-449.
10
Predictive value of 10-year atherosclerotic cardiovascular disease risk equations from the China-PAR for new-onset lower extremity peripheral artery disease.中国动脉粥样硬化性心血管病风险评估系统（China-PAR）中10年动脉粥样硬化性心血管病风险方程对新发下肢外周动脉疾病的预测价值
Front Cardiovasc Med. 2022 Oct 4;9:933054. doi: 10.3389/fcvm.2022.933054. eCollection 2022.

引用本文的文献

1
Vasoactive Drug Therapy and Clinical Nursing of Patients with Cardiovascular Disease.心血管疾病患者的血管活性药物治疗与临床护理。
Contrast Media Mol Imaging. 2022 Sep 21;2022:5659513. doi: 10.1155/2022/5659513. eCollection 2022.
2
Using Multiple Statistical Methods to Derive Dietary Patterns Associated with Cardiovascular Disease in Patients with Type 2 Diabetes: Results from a Multiethnic Population-Based Study.运用多种统计方法推导2型糖尿病患者中与心血管疾病相关的饮食模式：一项基于多民族人群研究的结果
Evid Based Complement Alternat Med. 2022 Aug 9;2022:2802828. doi: 10.1155/2022/2802828. eCollection 2022.
3
Chronic infusion of ELABELA alleviates vascular remodeling in spontaneously hypertensive rats via anti-inflammatory, anti-oxidative and anti-proliferative effects.
ELABELA 的慢性输注通过抗炎、抗氧化和抗增殖作用缓解自发性高血压大鼠的血管重构。
Acta Pharmacol Sin. 2022 Oct;43(10):2573-2584. doi: 10.1038/s41401-022-00875-w. Epub 2022 Mar 8.
4
ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway.埃贝拉通过抑制 NADPH 氧化酶/ROS/NLRP3 炎性小体通路来减轻脱氧皮质酮醋酸盐/盐诱导的高血压和肾脏损伤。
Cell Death Dis. 2020 Aug 22;11(8):698. doi: 10.1038/s41419-020-02912-0.